[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-380358-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-380358-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","recurrentmetastatic-nasopharyngeal-carcinoma-treatment-from-present-to-future-where-are-we-and-where-are-we-heading","Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future - Where Are We and Where Are We Heading?","","Opinion statement and review content focus on recurrent or metastatic nasopharyngeal carcinoma (NPC), emphasizing its distinctive anatomy and biology compared with other head and neck cancers. It outlines WHO subtypes linked to Epstein-Barr virus (EBV) status and discusses why recurrence and distant metastasis remain major causes of death despite modern local and locally advanced therapies. The review summarizes current platinum-based chemotherapy, the uncertain role of immune checkpoint inhibitors for NPC, and the need for research to define optimal treatment sequencing across EBV-positive and EBV-negative disease.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/recurrentmetastatic-nasopharyngeal-carcinoma-treatment-from-present-to-future-where-are-we-and-where-are-we-heading/380358/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/recurrentmetastatic-nasopharyngeal-carcinoma-treatment-from-present-to-future-where-are-we-and-where-are-we-heading/380358.png","ImageObject",300,407,{"name":42,"@type":43},"Bintang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is NPC considered distinct from other head and neck cancers?","Question",{"text":63,"@type":64},"NPC differs in histology, epidemiology, molecular pathogenesis, and treatment response. WHO subtype distinctions also relate to Epstein-Barr virus (EBV) presence and other histopathology features.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are the common challenges in treating recurrent/metastatic NPC?",{"text":68,"@type":64},"Many patients recur and die from distant metastasis or locoregional relapse. Even with improved survival for locally advanced disease, a substantial proportion still develops recurrent/metastatic disease, with poor overall survival in advanced stages.",{"name":70,"@type":61,"acceptedAnswer":71},"What current treatments are highlighted for recurrent/metastatic NPC?",{"text":72,"@type":64},"Current recommendations center on platinum-based combination chemotherapy. The review also discusses targeted and immunotherapies and notes the ongoing challenge that immune checkpoint inhibitors have not been FDA-approved specifically for NPC to date.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},380358,1790493882,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Current Treatment Options in Oncology (2023) 24:1138–1166 DOI 10.1007/s11864-023-01101-3  \nRecurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future:  \nWhere Are We and Where Are We Heading?  \nJuan Jose Juarez‑Vignon Whaley, MD1 Michelle Afkhami, MD2  \nMykola Onyshchenko, MD, PhD3 Erminia Massarelli, MD, PhD, MS3 Sagus Sampath, MD4  \nArya Amini, MD4  \nDiana Bell, MD2 Victoria M. Villaflor, MD3,*  \nAddress  \n1 Health Science Research Center, Faculty of Health Science, Universidad Anahuac Mexico, State of Mexico, Naucalpan de Juárez, Mexico  \n2 Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA *,3 Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, 1500 East Duarte Road. , Duarte, CA 91010, USA  \n[Email: vvillaflor@coh.org](Email: vvillaflor@coh.org)  \n4 Department of Radiation Oncology, City of Hope Comprehensive Cancer Center Duarte, Duarte, CA, USA  \nPublished online: 15 June 2023 © The Author(s) 2023  \nKeywords Nasopharyngeal carcinoma · Recurrent/metastatic disease · Management NPC · Epstein-Barr virus positivity · Targeted therapy · Immunotherapy · Clinical trials  \nOpinion statement  \nNasopharyngeal carcinoma (NPC) is distinct in its anatomic location and biology from other epithelial head and neck cancer (HNC) . There are 3 WHO subtypes, which considers the presence of Epstein-Barr virus (EBV) and other histopathology features. Despite the  \nsurvival benefit obtained from modern treatment modalities and techniques specifically in the local and locally advanced setting, a number of patients with this disease will recur and subsequently die of distant metastasis, locoregional relapse, or both. In therecurrent setting, the ideal therapy approach continues to be a topic of discussion and current recommendations are platinum-based combination chemotherapy. Phase III clinical trials which led to the approval of pembrolizumab or nivolumab for head and necksquamous cell carcinoma (HNSCC) specifically excluded NPC. No immune checkpoint inhibitor therapy, to date, has been approved by the FDA to treat NPC although the National Comprehensive Cancer Network (NCCN) recommendations do include use of these agents. Hence, this remains the major challenge for treatment options. Nasopharyngeal carcinoma is challenging as it is really 3 different diseases, and much research is required to determine best options and sequencing of those options. This article is going to address the data to date and discuss ongoing research in EBV + and EBV – inoperable recurrent/ metastatic NPC patients.  \nIntroduction  \nNasopharyngeal carcinoma (NPC) arises in the nasopharynx and differs from other head and neck cancer (HNC) in histology, epidemiology, molecular pathogenesis, and treatment response. In 2020, there were 133,354 new cases and 80,008 deaths in both sexes and all ages [1] . Its etiology involves factors, such as genetic predisposition, Epstein-Barr virus (EBV) infection, and environmental risk factors (smoking, saltcured food) . It is a rare malignant epithelial tumor endemic to Southern and Southeast China. Histologically, NPC is categorized by The World Health Organization into three types. Keratinizing squamous cell carcinoma (type 1) consists of well-differentiated cells that produce keratin. Nonkeratinizing carcinoma, which can be differentiated (type 2) or undifferentiated (type 3), these do not produce keratin. Basaloid squamous cell carcinoma (subset of type 3) is also nonkeratinizing and characterized by less differentiated cell types and is associated with aggressive disease [2] . Subtypes II and III are strongly related to EBV infection, the main risk factor for NPC and subtype III is the most predominant histological subtype in Asia, whereas, in non-endemic regions, NPC type 1 is the most frequent histological subtype [3, 4] .  \nEBV driven NPC is of particular interest in that up to 20% of all cancers may be related to a bacterial or viral infection ","cbCaibJ7G8hm3ACE","https://ap.wps.com/l/cbCaibJ7G8hm3ACE","pdf",590000,29,"English","# Opinion statement\n# Introduction\n# Tumor biology\n## Molecular and immunohistochemistry\n## Next generation sequencing","[{\"question\":\"Why is NPC considered distinct from other head and neck cancers?\",\"answer\":\"NPC differs in histology, epidemiology, molecular pathogenesis, and treatment response. WHO subtype distinctions also relate to Epstein-Barr virus (EBV) presence and other histopathology features.\"},{\"question\":\"What are the common challenges in treating recurrent/metastatic NPC?\",\"answer\":\"Many patients recur and die from distant metastasis or locoregional relapse. Even with improved survival for locally advanced disease, a substantial proportion still develops recurrent/metastatic disease, with poor overall survival in advanced stages.\"},{\"question\":\"What current treatments are highlighted for recurrent/metastatic NPC?\",\"answer\":\"Current recommendations center on platinum-based combination chemotherapy. The review also discusses targeted and immunotherapies and notes the ongoing challenge that immune checkpoint inhibitors have not been FDA-approved specifically for NPC to date.\"}]","Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future - Where Are We and Where Are We Heading? | PDF",1790239854,73]